Oregovomab
1 clinical trial
2 products
3 abstracts
5 indications
1 target
Indication
Pancreatic adenocarcinomaIndication
Pancreatic CancerIndication
Pancreatic Cancer, Stage IIIndication
Stage IIB Pancreatic CancerIndication
Stage III Pancreatic CancerTarget
MUC16Abstract
Phase 2, single arm clinical trial to evaluate the safety and activity of oregovomab and niraparib as a combinatorial immune priming strategy in subjects with platinum sensitive recurrent ovarian cancer: FLORA-4 study.Org: Department of OB/GYN, Duke Cancer Institute of Duke University Health System, CanariaBio, Inc,
Clinical trial
A Phase II Study of Neoadjuvant Chemotherapy With and Without Immunotherapy to CA125 (Oregovomab) Followed by Hypofractionated Stereotactic Radiotherapy & Concurrent HIV Protease Inhibitor Nelfinavir in Locally Advanced Pancreatic CancerStatus: Completed, Estimated PCD: 2018-04-01
Abstract
Oregovomab and non-platinum chemotherapy in PARP inhibitor-resistant ovarian, fallopian tube, or primary peritoneal cancer patients not candidates for platinum retreatment: A multicenter, two-cohort, single-arm phase 2 trial (OPERA/KGOG 3065/APGOT-OV6).Org: Yonsei University College of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea University College of Medicine, Seoul National University Bundang Hospital,
Abstract
FLORA-5/GOG3035: Chemo-immunotherapy (paclitaxel-carboplatin-oregovomab [PCO] vs chemotherapy (paclitaxel-carboplatin-placebo [PCP]) as front-line treatment in patients with advanced epithelial ovarian cancer (EOC)—Phase III, double blind, placebo controlled, global, multinational study.Org: National Cancer Center, Goyang-Si, Gyeonggi-Do, South Korea, CanariaBio, Inc, Lexington, MA, CanariaBio, Inc, Singapore, Severance Hospital, Yonsei University Health System, Seoul, South Korea, John Muir Health, Walnut Creek, CA,
Product
Oregovomab + HiltonolProduct
oregovomab + niraparib